Arcturus Therapeutics Holdings Inc (NAS:ARCT)
$ 17.9 -0.74 (-3.97%) Market Cap: 484.87 Mil Enterprise Value: 297.15 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 77/100

Arcturus Therapeutics Holdings Inc To Present At Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day Transcript

Apr 03, 2023 / 06:10PM GMT
Release Date Price: $25.7 (+7.22%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Okay. Great. Well, good afternoon, everyone. Thanks for joining us for another fireside chat discussion. Here to my left are Arcturus' CEO, Joe Payne. And to his left is CFO, Andy Sassine. I'm Seamus Fernandez, one of the biopharma analysts here at Guggenheim Securities. And this is our annual rare disease and genetic medicines conference. So in that context, of course, as an mRNA company, we sort of have to start with vaccines, and then we'll jump right into the rare disease side of things.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

So Joe, maybe just to start us off, I will start with a couple of vaccines questions. So on the cusp of data from Meiji in the head-to-head trial, maybe you can just recap the design of the study for investors. And then maybe just help us understand what success might look like from an approval standpoint and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot